Last updated: 2026-09-16 09:45:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
PROCEPT BioRobotics Corporation (PRCT) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $19.51, with a market capitalisation of $1.20B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.67 to $40.10. This page covers its latest market performance, valuation, price trends and company information.
$1.20B | |
$19.35 | |
$103.81 | |
$15.38 | |
$19.30 | |
563.00 | |
1.57M | |
-- | |
$40.10 | |
$16.67 | |
-- | |
-- |
PROCEPT BioRobotics Corporation (PRCT) is trading at $19.51 in pre-market trading as of 2026-09-16 09:19:00, up 1.09% ($0.21) from the previous close of $19.30
Pre-market trading shows how investors are pricing PRCT before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, PROCEPT BioRobotics Corporation (PRCT) moved from $22.76 to $19.51, representing a decline of 14.28% ($3.25).
The stock traded between $19.23 and $22.84 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.48 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 12.1%
PRCT is currently trading at $19.51, placing it 12.1% of the way from its 52-week low of $16.67 to its 52-week high of $40.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 888 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PROCEPT BioRobotics Corporation (PRCT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.